Longitudinal comparison of IL-6, IL-10, and IL-12 cytokine profiles in adult and childhood-onset systemic lupus erythematosus

被引:0
|
作者
Pelicari, Karina de Oliveira [1 ]
Postal, Mariana [1 ]
Sinicato, Nailu Angelica [1 ,2 ]
Londe, Ana Carolina [1 ,3 ]
Fernandes, Paula Teixeira [4 ]
Marini, Roberto [5 ]
Costallat, Lilian Tereza Lavras [6 ]
Appenzeller, Simone [1 ,6 ,7 ]
机构
[1] Univ Estadual Campinas, Sch Med Sci, Rheumatol Lab, Campinas, Brazil
[2] Univ Estadual Campinas, Sch Med Sci, Child & Adolescent Hlth Grad Program, Campinas, Brazil
[3] Univ Estadual Campinas, Sch Med Sci, Med Physiopathol Grad Program, Campinas, Brazil
[4] Univ Estadual Campinas, Fac Phys Educ, Dept Sport Sci, Campinas, Brazil
[5] Univ Estadual Campinas, Sch Med Sci, Dept Pediat, Campinas, Brazil
[6] Univ Estadual Campinas, Sch Med Sci, Dept Orthoped Rheumatol & Traumatol, Campinas, Brazil
[7] Univ Estadual Campinas, Fac Med Sci, Dept Med, Cidade Univ, BR-13083970 Campinas, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
DISEASE-ACTIVITY; TNF-ALPHA; EGYPTIAN PATIENTS; REVISED CRITERIA; SLE; EXPRESSION; COHORT; SERUM; INTERLEUKIN-10; CLASSIFICATION;
D O I
10.1016/j.jtauto.2022.100158
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To compare the levels of Th1 (IL-12) and Th2 (IL-6 and IL10) cytokines over a two-year period among systemic lupus erythematosus patients with childhood-onset (cSLE), adult-onset (sSLE), and healthy controls, and correlate with their clinical, laboratory, and treatment manifestations. Methods: The study included 63 patients with cSLE [57 (90%) women; mean age 19.7 +/- 4.3 years (range = 10-29); mean disease duration 7.3 +/- 4.2 years (range 2-15)], 67 patients with aSLE [65 (97%) women; mean age of 39.9 +/- 11.8 years (range 21-68); disease duration 7.7 +/- 3.1 years (range 4-16)], and 40 healthy controls [36 (90%) women; mean age of 29.6 +/- 10 years (range 12-49)]. cSLE and aSLE patients were paired by disease duration. Clinical and laboratory manifestations, disease activity (SLEDAI), cumulative damage (SDI), and current drug exposures were evaluated. Symptoms of anxiety and depression were evaluated by the Beck inventory (BAI and BDI, respectively). Th1 (IL-12) and Th2 (IL-6 and IL-10) cytokines were measured by the ELISA test. Data were collected at four different time points (TI, TII, TIII, and TIV) and compared by non-parametric tests. Results: IL-6 levels were significantly higher in aSLE patients compared to healthy controls at times I, II, and III (TI p = 0.013, TII p = 0.015, TIII p = 0.004, and TIV p = 0.634). However, no difference was observed between cSLE patients and healthy controls (TI p = 0.223, TII p = 0.613, TIII p = 0.341, and TIV p = 0.977). In addition, no difference was observed between aSLE and cSLE patients (TI p = 0.377, TII p = 0.123, TIII p = 0.105, and TIV p = 0.591). The levels of IL-12 were significantly higher in cSLE patients compared to healthy controls at all time points (TI p = 0.04, TII p < 0.001, TIII p = 0.015, and TIV p = 0.021). aSLE patients showed significantly elevated levels when compared to healthy controls at time III and IV (TI p = 0.752, TII p = 0.827, TIII p = 0.011*, and TIV p < 0.001*). cSLE patients showed significantly higher levels than aSLE patients at times I and II (TI p = 0.07*, TII p < 0.001*, TIII p = 0.998, and TIV p = 0.140). In aSLE patients, IL-6 was associated with headache (p = 0.006), arthritis (p = 0.044), and nephritis (p = 0.012); IL-10 was associated with nephritis (p = 0.043), hypocomplementemia (p = 0.001), and disease activity (p = 0.001); in these patients, IL-12 was associated with alopecia (p = 0.025) and leukopenia (p = 0.044). In cSLE patients, IL-6 was associated with arthritis (p = 0.022) and malar rash (p = 0.012). Conclusion: aSLE and cSLE patients with long disease duration present similar levels of cytokines, despite differences in clinical activity patterns over time.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus
    Chun, Hye-Young
    Chung, Jae-Wook
    Kim, Hyoun-Ah
    Yun, Jeong-Moon
    Jeon, Ja-Young
    Ye, Young-Min
    Kim, Seung-Hyun
    Park, Hae-Sim
    Suh, Chang-Hee
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (05) : 461 - 466
  • [2] Cytokine IL-6 and IL-10 as Biomarkers in Systemic Lupus Erythematosus
    Hye-Young Chun
    Jae-Wook Chung
    Hyoun-Ah Kim
    Jeong-Moon Yun
    Ja-Young Jeon
    Young-Min Ye
    Seung-Hyun Kim
    Hae-Sim Park
    Chang-Hee Suh
    [J]. Journal of Clinical Immunology, 2007, 27 : 461 - 466
  • [3] IL-6 and IL-10 levels in childhood-onset systemic lupus erythematosus: are they different in the active and inactive forms of the disease?
    Cavalcanti, A.
    Santos, R. S. N.
    Mesquita, Z.
    Duarte, A. L. B. P.
    Lucena-Silva, N.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : S72 - S72
  • [4] Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes
    Liu, TF
    Jones, BM
    [J]. CYTOKINE, 1998, 10 (02) : 140 - 147
  • [5] IL-12 and IL-10 polymorphisms and their effects on cytokine production
    Yilmaz, V
    Yentür, SP
    Saruhan-Direskeneli, G
    [J]. CYTOKINE, 2005, 30 (04) : 188 - 194
  • [6] IL-6, IL-10 and IL-4 expression and cross-talk in patients with systemic lupus erythematosus (SLE).
    Honda, M
    Nand, R
    Mandyam, R
    Mengesha, E
    Wallace, DJ
    Metzger, A
    Bharier, B
    Klineberg, JR
    Morris, R
    Linker-Israeli, M
    [J]. ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S39 - S39
  • [7] Interleukins IL-6, IL-8, IL-10, IL-12 and periimplant disease. An update
    Candel-Marti, Maria-Eugenia
    Flichy-Fernandez, Antonio-Juan
    Alegre-Domingo, Teresa
    Ata-Ali, Javier
    Penarrocha-Diago, Maria A.
    [J]. MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL, 2011, 16 (04): : E518 - E521
  • [8] IL-10 revisited in systemic lupus erythematosus
    Biswas, Swayanka
    Bieber, Katja
    Manz, Rudolf Armin
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [9] A comparison between systemic lupus erythematosus and chronic cutaneous lupus regarding the levels of IL-10 and of the proinflammatory cytokines, IL-6 and TNF alpha
    Geanta, M.
    Alecu, M.
    Benea, V
    Georgescu, S.
    [J]. ALLERGY, 2010, 65 : 465 - 465
  • [10] Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus
    Nepal, Desh
    Gazeley, David
    [J]. RHEUMATOLOGY, 2023, 62 (12): : 3804 - 3810